Your session is about to expire
← Back to Search
Celecoxib for Pharmacokinetics of Celecoxib
Study Summary
This trial found that celecoxib is effective in reducing postoperative pain in adults, while children use celecoxib more rapidly and require higher doses.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am older than 12 years but younger than 2 years.My child is 2-12 years old, in remission from leukemia or lymphoma, and receiving maintenance chemotherapy.I have been diagnosed with acute myeloid leukemia (AML).My liver tests are more than twice the normal limit.I am taking medications like fluconazole, amiodarone, or oxandrolone.I am on high doses of methotrexate.My child has cancer that does not involve the blood.My child is only having a bone marrow aspiration.I have taken celecoxib in the last 7 days.I have had peptic ulcers in the past.I am currently taking rifampin or phenobarbital.
- Group 1: Phase II: Group B: Study drug (Celecoxib 7 mg/kg)
- Group 2: Phase II: Group C: Study drug (Celecoxib 14 mg/kg)
- Group 3: Phase I: Study drug Group 1 (Celecoxib 7 mg/kg)
- Group 4: Phase II: Group A: Placebo
- Group 5: Phase I: Study drug Group 2 (Celecoxib 14 mg/kg)
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the upper bound of participants in this experiment?
"This trial is no longer accepting new participants. The original posting date was December 1st, 2022 and the last update occurred on August 19th, 2022. However, there are currently one study involving celecoxib which has yet to reach its recruitment goal and 40 Phase II studies for Study Drug (Celecoxib 7 mg/kg) still in search of volunteers."
Does this study allow seniors as participants?
"This trial is recruiting participants between the ages of 2 and 12. There are 9 studies for minors and 31 studies available to those over 65 years old."
What are the principal objectives of this research endeavor?
"The primary aim of this clinical trial seeks to evaluate the cerebrospinal fluid (CSF) levels of celecoxib administered in 120-180 minutes following ingestion. Secondary goals include determining plasma peak concentration, pharmacogenetic data from CYP2C9 genotypes, and a graph plotting pain scores against total plasma concentrations."
What clinical applications do researchers most commonly utilize Celecoxib 7 mg/kg for during Phase II: Group B?
"Group B of Phase II of this study drug (Celecoxib 7 mg/kg) is designed to remedy pain, primary dysmenorrhoea, and rheumatoid arthritis."
What risks are associated with utilizing Celecoxib 7 mg/kg in Phase II: Group B?
"Our Power team gave Phase II: Group B: Study drug (Celecoxib 7 mg/kg) a safety score of 2, as this is still only in the second phase and while there are indications that it may be safe, efficacy has not yet been established."
Are there any vacancies for participants in this investigation?
"This trial is no longer enrolling participants. Initially posted on December 1st 2022, the study was last edited on August 19th 2022. If other studies are being explored, there is one clinical trial for celecoxib and forty Phase II: Group B trials that require additional volunteers."
Who meets the eligibility criteria for this trial?
"This trial is recruiting 65 minors between the ages of 2 and 12 that have been prescribed celecoxib. Specifically, these young candidates should be undergoing chemotherapy for a hematological cancer or lymphoma at CHEO; also, all participants must have achieved remission approximately 6 months prior to commencement."
Share this study with friends
Copy Link
Messenger